...
首页> 外文期刊>Tumori. >c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.
【24h】

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

机译:乳腺癌患者组织和血清中c-erbB-2蛋白水平:可能有用的临床相关性。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS AND BACKGROUND: The aims of this study were to assess the clinical utility of circulating preoperative HER-2 extracellular domain p105 detected by enzyme immunoassay (ELISA), to compare the tissue expression of HER-2eu determined by immunohistochemistry (IHC), to correlate prognostic factors including tumor size, nodal involvement, and hormone receptor status, and to analyze the prognostic significance of the marker in relation to clinical outcome as measured by disease-free and overall survival. METHODS: In this study, we enrolled 108 consecutive patients with breast carcinoma, and obtained serum samples and frozen tumor tissues. We compared them with 57 women with fibroadenoma and 63 healthy women as controls. RESULTS: Univariate ANOVA analysis showed no relationship between HER-2eu in tissue and serum. Preoperative serum levels of p105 were significantly higher in breast cancer patients than in women with benign disease or healthy women. Concerning the correlation between p105, HER-2eu tissue expression, and the other prognostic factors, a statistically significant correlation between high serum p105 levels and ER-negative status in breast cancer patients was found. Kaplan-Meier analysis confirmed that patients with positive HER-2eu tissue expression had a significantly shorter survival than those with negative expression. Analysis with the Cox model demonstrated that tumor size was the only significant independent prognostic factor. CONCLUSIONS: This research failed to demonstrate a relationship between preoperative tissue overexpression and circulating HER-2eu, suggesting that p105 does not represent a valid alternative to predict a worsened prognosis in breast cancer, but it could be a diagnostic marker to discriminate healthy subjects from breast cancer patients.
机译:目的与背景:这项研究的目的是评估酶联免疫吸附测定(ELISA)检测的术前循环HER-2细胞外结构域p105的临床应用,比较免疫组织化学(IHC)测定的HER-2 / neu的组织表达,关联肿瘤大小,淋巴结受累和激素受体状态等预后因素,并分析该标志物与无病生存期和总生存期相关的临床预后的预后意义。方法:在这项研究中,我们招募了108名连续的乳腺癌患者,并获得了血清样本和冷冻的肿瘤组织。我们将他们与57名患有纤维腺瘤的女性和63名健康女性作为对照进行了比较。结果:单因素方差分析表明组织中HER-2 / neu与血清无相关性。乳腺癌患者的术前血清p105水平显着高于患有良性疾病的女性或健康女性。关于p105,HER-2 / neu组织表达与其他预后因素之间的相关性,发现乳腺癌患者中高血清p105水平与ER阴性状态之间具有统计学意义的相关性。 Kaplan-Meier分析证实,HER-2 / neu组织阳性表达的患者比阴性表达的患者生存期明显缩短。用Cox模型进行的分析表明,肿瘤大小是唯一重要的独立预后因素。结论:这项研究未能证明术前组织过表达与循环HER-2 / neu之间的关系,提示p105不能代表预测乳腺癌预后恶化的有效选择,但它可能是鉴别健康受试者的诊断指标来自乳腺癌患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号